Zürcher Kantonal Bank
VC Fund
Zürich, Switzerland
Zürcher Kantonal Bank is a VC fund in Zürich focused on Health Care and Biotechnology. Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
- Total investments:
- 207
- Last investment:
- Lead investor:
- 13%
- Fund size:
- $150M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Zürcher Kantonal Bank invests in
Stages Zürcher Kantonal Bank invests in
Countries Zürcher Kantonal Bank invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $1M–$6M
- Series A
- $2.1M–$13M
- Series B
- $1.9M–$20M
Investment Focus
Industry
- Health Care 36 (17%)
- Biotechnology 29 (14%)
- Medical Device 28 (14%)
- Software 26 (13%)
- Information Technology 22 (11%)
Stage
- Seed 72 (35%)
- Series A 52 (25%)
- Series B 18 (9%)
- Venture - Series Unknown 13 (6%)
- Funding Round 11 (5%)
Country
- Switzerland 139 (67%)
- Germany 2 (1%)
- Japan 1 (0%)
- Spain 1 (0%)
- United Kingdom 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Heinz Kunz
Executive Board
|
Executive Board | Total investments: 0 | Find email | |
Christoph Weber
Executive Board
|
Executive Board | Total investments: 0 | Find email | |
Daniel Previdoli
Executive Board
|
Executive Board | Total investments: 0 | Find email | |
Jurg Buhlmann
Executive Board
|
Executive Board | Total investments: 0 | Find email | |
Markus Bachofen
Executive Board
|
Executive Board | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cotierra is a climate technology and AgTech company that develops decentralized biochar systems for regenerative agriculture. | $3M / Seed / Sep 29, 2026 | ||
| There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need. | $25M / Venture - Series Unknown / Sep 17, 2026 | ||
| DataHow AG is a spin-off of ETH Zurich that specializes in data analytics and process modelling for the biopharmaceutical and chemical industries. The company provides digital solutions and consulting services for process monitoring, optimization, and scale-up. Their focus is on reducing effort, risks, and costs in process development whileenhancing the understanding of complex manufacturing processes. | Series A / Sep 02, 2026 | ||
| xorlab is a Swiss cybersecurity company providing specialized, machine-intelligent defense against highly engineered, sophisticated and targeted email attacks. Founded in 2015 and spun out of ETH’s Laboratory of Software Technology, xorlab has grown to a team of 14 dedicated security professionals and passionate software engineers. The company,with its ActiveGuard Defense Platform, now already protects more than 50k mailboxes from leading financial service providers and high-tech industrial companies in Germany and Switzerland, and processes more than 1.5 million emails per day. xorlab empowers its customers to detect and stop emerging attacks at first sight, resulting in a smaller risk of breach, fewer incidents and lower operating cost overall. | $5.8M / Series A / Sep 01, 2026 | ||
| At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommondiseases with significant unmet medical needs. | $2.8M / Pre-Seed / Jul 21, 2026 | ||
| CCRAFT is a manufacturer of thin-film lithium niobate and photonic integrated circuits. | $7.8M / Seed / Jul 02, 2026 | ||
| Cultivated Biosciences is a Food Production Company. | $6M / Seed / Apr 21, 2026 | ||
| Impossible Materials envisions future customers consuming more sustainable products produced in a circular economy. They contribute to this future by selling cellulose-based products to businesses. Plant-based cellulose white pigment and opacifier solutions have been developed for a variety of industries. | $15.6M / Series A / Mar 10, 2026 | ||
| Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.8M / Seed / Mar 04, 2026 | ||
| Clee Medical believes the rapid growth of neurotech is constrained by inefficiencies in surgical tools and techniques. | Seed / Feb 25, 2026 | ||
| See all 207 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Zürcher Kantonal Bank invest in?
Zürcher Kantonal Bank invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 207 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Zürcher Kantonal Bank's check size?
Zürcher Kantonal Bank typically joins rounds of $1M–$6M at Seed, $2.1M–$13M at Series A and $1.9M–$20M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Zürcher Kantonal Bank participates in.
How do I contact Zürcher Kantonal Bank?
Public channels for Zürcher Kantonal Bank include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zürcher Kantonal Bank?
The team at Zürcher Kantonal Bank includes Heinz Kunz (Executive Board), Christoph Weber (Executive Board) and Daniel Previdoli (Executive Board), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
